|Articles|July 7, 2011

google plus one (home page)

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Subscribe Now!

Related Content

FDA accepts roflumilast cream 0.3% sNDA to treat plaque psoriasis in children 2 to 5 years

ByJoshua Fitch, Senior Editor

November 17th 2025

Long-term outcomes of lentiviral gene therapy for ADA-deficient severe combined immunodeficiency

ByMorgan Ebert, Managing Editor

November 16th 2025

Study: Child maltreatment rates declined overall, but disparities persisted across sex and race

ByMorgan Ebert, Managing Editor

November 15th 2025

FDA updates Elevidys labeling with boxed warning and revised indication following reports of fatal liver injury

ByMorgan Ebert, Managing Editor

November 14th 2025

Tapinarof cream, 1% (VTAMA) shows early improvements in pediatric atopic dermatitis

ByMorgan Ebert, Managing Editor

November 14th 2025

Latest CME

Video

Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)

Anil K. Agarwal, MD, FACP, FASN, FNKF, FASDIN; Jay B. Wish, MD

Multimedia

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

Glenn M. Chertow, MD, MPH; Anjay Rastogi, MD, PhD

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Multimedia

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc

Multimedia

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Frank B. Cortazar, MD; Lindsay S. Lally, MD

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

Video

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

google plus one (home page)

Newsletter

Related Content

FDA accepts roflumilast cream 0.3% sNDA to treat plaque psoriasis in children 2 to 5 years

Long-term outcomes of lentiviral gene therapy for ADA-deficient severe combined immunodeficiency

Study: Child maltreatment rates declined overall, but disparities persisted across sex and race

FDA updates Elevidys labeling with boxed warning and revised indication following reports of fatal liver injury

Tapinarof cream, 1% (VTAMA) shows early improvements in pediatric atopic dermatitis

Latest CME

Clinical Consultations™: Addressing Elevated Phosphate Levels in Patients with END-STAGE Kidney Disease (ESKD)

Advances In: Managing Hyperphosphatemia in Chronic Kidney Disease – Bridging Treatment Gaps With Novel Therapies

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Burst CME™: Addressing Inadequate Response to Anti-TNF Therapy in Patients With Rheumatoid Arthritis

Community Practice Connections™: Cases and Conversations – Keeping Up with Novel Approaches to Managing ANCA-Associated Vasculitis

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Trending on Contemporary Pediatrics

Study: Child maltreatment rates declined overall, but disparities persisted across sex and race

Long-term outcomes of lentiviral gene therapy for ADA-deficient severe combined immunodeficiency

FDA accepts roflumilast cream 0.3% sNDA to treat plaque psoriasis in children 2 to 5 years